ArticleFrontiers in oncology2025
Analysis of lymph node recurrence patterns and risk factors in locally advanced esophageal carcinoma following neoadjuvant therapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although neoadjuvant therapy followed by surgery is the standard treatment for resectable locally advanced esophageal carcinoma, heterogeneity exists in neoadjuvant regimens within real-world practice. This study characterizes lymph node recurrence (LNR) patterns and compares LNR risk factors across different neoadjuvant approaches to better elucidate therapeutic efficacy. Methods: Data were collected from esophageal carcinoma (EC) patients who underwent surgery following neoadjuvant therapy between January 2018 and December 2023. Neoadjuvant regimens included neoadjuvant chemotherapy (NCT), neoadjuvant chemoimmunotherapy (NICT), and neoadjuvant chemoradiotherapy (NCRT)/neoadjuvant chemoradiotherapy combined with immunotherapy (NCRT/NICRT). Regional lymph node stations were defined per the Japanese Esophageal Society (JES) criteria. Cox proportional hazards models were used to identify factors associated with LNR. Results: This study enrolled 658 patients, including 195 with postoperative LNR. Among all EC cases, the most frequent recurrence sites were No. 106tb (5.5%), No. 109 (5.5%), and No. 104 (8.7%). The most frequent recurrence sites in the NCT group were No. 104 (10.0%) and No. 106tb (7.9%); in the NICT group, No. 104 (8.2%) was the most common; in the NCRT/NICRT group, No. 101 (7.0%) and No. 104 (7.0%) demonstrated the highest recurrence rates. In upper thoracic EC, No. 101, No. 104, and No. 105 were common recurrence sites with metastasis rates exceeding 5%; in mid-thoracic EC, No. 104 (11.9%) showed the highest recurrence frequency; in lower thoracic and gastroesophageal junction EC, No. 104 (5.5%) and No. 16 (4.8%) were frequent recurrence locations. Lymph node dissection count and ypT and/or ypN stage correlated with recurrence risk across neoadjuvant regimens. Adjuvant radiotherapy demonstrated lower lymph node metastasis rates in the tracheoesophageal groove and upper mediastinal LNR. Conclusions: The tracheoesophageal groove and supraclavicular lymph nodes represent common recurrence sites in neoadjuvant therapy and upper thoracic EC. Lower thoracic and gastroesophageal junction EC require vigilance for the risk of supraclavicular nodal metastasis. Lymph node yield and T/N stages correlate with recurrence risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.